Mark Schoenberg - Oct 31, 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Stock symbol: URGN
Transactions as of: Oct 31, 2022
Transactions value $: -$3,057
Form type: 4
Date filed: 11/2/2022, 04:31 PM
Previous filing: Aug 25, 2022
Next filing: Jan 23, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+500	+2.11%		24.2K	Oct 31, 2022	Direct	F1
transaction	URGN	Ordinary Shares	Sale	-$3.06K	-258	-1.07%	$11.85	24K	Oct 31, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-500	-50%	$0.00	500	Oct 31, 2022	Ordinary Shares	500		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3	The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.